Study Reveals Unintended Food Waste Consequence of Popular Weight Loss Medications

Nov 22, 2024 at 9:51 PM
According to a recent study, an interesting phenomenon has emerged among those taking popular weight loss medications like Ozempic, Wegovy, and Mounjaro. One in four individuals found themselves disposing of more food after starting these drugs. This finding, published in the scientific journal “Nutrients,” sheds light on an unexpected side effect of GLP-1 receptor agonists.

Uncover the Hidden Impact of Weight Loss Drugs on Food Waste

Initial Survey Findings

Researchers conducted a survey among more than 500 current GLP-1 users across the country. They asked a series of questions online, including one about the change in average daily calorie consumption compared to before starting the medication. Additionally, respondents were asked if they agreed with the statement “I waste more of the food that I purchase.” The survey results showed that 25% agreed, while 61% disagreed.This indicates that there is a significant difference in perception among users. Those on the medication for a longer period were less likely to agree with the waste statement, suggesting they had made adjustments and learned to better manage their food purchasing and consumption.

Impact on Eating Habits

As the study noted, these drugs have a profound impact on eating habits. They reduce appetite, slow down gastric emptying, and shift food preferences. This leads to a change in the way people eat and interact with food.For example, some users initially experienced nausea, which was a common side effect. This side effect seemed to be related to the increased likelihood of wasting food. However, as they adjusted to the medication, they were able to better manage these issues and reduce food waste.

Increasing Prevalence and Younger Users

The use of GLP-1 drugs has been on the rise. About 12% of U.S. adults reported having taken at least one dose, and 6% were actively using the medications. Additionally, 59% of adults claimed to have heard something about these medicines.A separate study earlier this year found that the monthly use of GLP-1 drugs has surged among younger people aged 12 to 25. From about 8,700 users a month in 2020, the number climbed to more than 60,000 a month in 2023, representing a nearly 600% increase.This shows that the impact of these drugs is not limited to a specific age group and is becoming more widespread.